Clinical Trial Update: Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients [Phase 1]

View source ↗

Summary

Phase 1 trial examining the bioavailability of tiotropium + olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• tiotropium + olodaterol fixed-dose combination (5 μg/5 μg)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED | Results posted: 2019-03-29